Results 281 to 290 of about 289,028 (352)

A Short Version of Carers' Quality of Life Questionnaire for Parkinsonism: Data from Progressive Supranuclear Palsy Network

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background and objectives Caregivers of progressive supranuclear palsy (PSP) patients frequently show significant distress. The Parkinsonism Carers quality of life (QoL) (PQoL Carer) is a valid tool evaluating the effect of PSP on caregivers' QoL.
Arianna Cappiello   +73 more
wiley   +1 more source

Prediction of the Mechanical Properties of the Additive Friction Stir‐Deposited Al2219 Using Machine Learning

open access: yesMaterials Genome Engineering Advances, EarlyView.
In this work, three prediction machine learning (ML) models (MLP, RBF, BP) are developed to predict the ultimate tensile strength (UTS) and elongation (EL) of the AFSDed Al2219 samples. ABSTRACT Additive friction stir deposition (AFSD) is an effective method for fabricating high‐performance deposits, with process parameters directly influencing the ...
Chan Wa Tam   +10 more
wiley   +1 more source

A PLP‐SEC Investigation of Di(Ethylene Glycol) Methyl Ether Methacrylate Radical Polymerization Propagation Kinetics in Solution

open access: yesMacromolecular Reaction Engineering, EarlyView.
The propagation rate coefficient of di(ethylene glycol) methyl ether methacrylate exhibits the same temperature dependency but is a factor of 12 higher in aqueous solution compared to bulk. Smaller increases are observed in ethanol and ethanol/water mixtures, with the value of the rate coefficient decreasing as the monomer concentration in solution is ...
Fatemeh Salarhosseini   +1 more
wiley   +1 more source

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

open access: yesObesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays   +9 more
wiley   +1 more source

Interoceptive Ability is Unrelated to Mental Health Symptoms: Evidence From a Large Scale Multi-Domain Psychophysical Investigation

open access: yes
Banellis L   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy